Results 81 to 90 of about 18,322 (221)

Development of a fluorometric microtiter plate-based enzyme assay for arylsulfatase B (MPS VI) using dried blood spots

open access: yesMolecular Genetics and Metabolism Reports, 2014
Mucopolysaccharidosis type VI or Maroteaux–Lamy syndrome is an autosomal recessive lysosomal storage disorder caused by deficiency of arylsulfatase B (ARS-B) enzyme activity.
Anirudh J. Ullal   +2 more
doaj   +1 more source

The human metabolic reconstruction Recon 1 directs hypotheses of novel human metabolic functions [PDF]

open access: yes, 2011
Metabolic network reconstructions formalize our knowledge of metabolism. Gaps in these networks pinpoint regions of metabolism where biological components and functions are "missing." At the same time, a major challenge in the post genomic era involves ...
Bernhard Ø Palsson   +2 more
core   +2 more sources

Multistage tandem mass spectrometry of chondroitin sulfate and dermatan sulfate [PDF]

open access: yesInternational Journal of Mass Spectrometry, 2011
Chondroitin/dermatan sulfate (CS/DS) is a glycosaminoglycan (GAG) found in abundance in extracellular matrices. In connective tissue, CS/DS proteoglycans play structural roles in maintaining viscoelasticity through the large number of immobilized sulfate groups on CS/DS chains. CS/DS chains also bind protein families including growth factors and growth
Alicia M, Bielik, Joseph, Zaia
openaire   +2 more sources

Pushing Frontiers for Proteoglycans

open access: yesProteoglycan Research, Volume 4, Issue 2, April 2026.
ABSTRACT Almost half of proteins have one or more post‐translational glycosylation modifications involving the addition of glycan structures. Proteoglycans are a class of glycosylated proteins with one or more glycosaminoglycan (GAG) chains covalently attached to the core protein.
Marissa L. Maciej‐Hulme
wiley   +1 more source

Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review [PDF]

open access: yes, 2012
INTRODUCTION: Despite evidence-based guidelines for venous thromboembolism prevention, substantial variability is found in practice. Many economic evaluations of new drugs for thromboembolism prevention do not occur prospectively with efficacy studies ...
Deborah J Cook   +4 more
core   +1 more source

The Dual Immunoregulatory Role of CREB3L1 Underlying Latent and Severe Tuberculosis Clinical Manifestation

open access: yesImmunology, Volume 177, Issue 4, Page 810-823, April 2026.
RNA‐seq of lungs and livers from Mycobacterium tuberculosis ‐infected mice with distinct disease outcomes revealed organ‐specific responses driven by differences in immune activity and bacterial burden. Meta‐analysis identified orthologous genes shared with human latent TB and mouse liver, with Creb3l1, Myo7b, Cyyr1 and Cbs differentially expressed and
Felipe T. Lima   +9 more
wiley   +1 more source

Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells

open access: yesBrazilian Journal of Medical and Biological Research, 2001
The anticlotting and antithrombotic activities of heparin, heparan sulfate, low molecular weight heparins, heparin and heparin-like compounds from various sources used in clinical practice or under development are briefly reviewed.
H.B. Nader   +12 more
doaj   +1 more source

Insights into the structure and dynamics of lysyl oxidase propeptide, a flexible protein with numerous partners [PDF]

open access: yes, 2018
Lysyl oxidase (LOX) catalyzes the oxidative deamination of lysine and hydroxylysine residues in collagens and elastin, which is the first step of the cross-linking of these extracellular matrix proteins.
Duclos, Bertrand   +6 more
core   +3 more sources

Advances in Bioprinting to Model Immune‐Mediated Skin Diseases

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 9, 6 March 2026.
This review explores how 3D bioprinting drives innovation in developing in vitro skin models that mimic immune‐mediated diseases. It highlights current technologies, key applications in studying skin pathologies, and emerging challenges. The review points toward future opportunities for improving disease modeling and advancing therapeutic and cosmetic ...
Andrea Ulloa‐Fernández   +4 more
wiley   +1 more source

Mucopolysaccharidosis VI

open access: yesOrphanet Journal of Rare Diseases, 2010
Mucopolysaccharidosis VI (MPS VI) is a lysosomal storage disease with progressive multisystem involvement, associated with a deficiency of arylsulfatase B leading to the accumulation of dermatan sulfate. Birth prevalence is between 1 in 43,261 and 1 in 1,
Harmatz Paul   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy